NYSE:QGENLife Sciences
Does Qiagen's Expanded QIAstat-Dx Infection and AMR Menu Reframe the Bull Case for QGEN?
Earlier in July 2026, QIAGEN N.V. highlighted its molecular testing portfolio for detecting Cyclospora during a large U.S. cyclosporiasis outbreak and launched a CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe for rapid bloodstream infection and antimicrobial resistance testing.
Together, these moves underscore how QIAGEN is positioning its QIAstat-Dx platform as a comprehensive tool for time-critical infectious disease and resistance diagnostics across clinical, research and...